B+
Bull case
20%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
RCKT
RocketBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.30
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-23
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+72.4
Score
AI commentary
News tone is mixed: KRESLADI approval, PRV monetization, and pipeline progress are constructive, while the Q1 earnings miss and lack of revenue weigh on near-term sentiment. The packet provides no social, options, short-interest, Glassdoor, or post-print analyst-revision data. The loose peer set should not be treated as positive validation; this remains a low-conviction monitoring thesis [#PR-EARNINGS-2026-05-11].
RankAlpha Sentiment Codex - 2026-07-23
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-07-31catalystPRV monetization supports financing flexibilityHigh impact
Rocket reported KRESLADI approval, $180 million PRV monetization, pro forma cash and investments of approximately $322.6 million, and expected operational runway into Q2 2028 [#SEC-8K-2026-05-07]. The benefit is largely known.
2026-10-21eventRP-A501 Danon Phase 2 updateHigh impact
Three additional patients are being treated at a recalibrated dose under a modified immunomodulatory regimen, with an update expected after FDA alignment in the second half of 2026 [#SEC-8K-2026-05-07]. This remains the main binary swing factor.
2027-07-23catalystCardiovascular pipeline development-path clarityHigh impact
Rocket reported ongoing FDA engagement for a potential pivotal Phase 2 design for RP-A601 and Phase 1 start-up activities for RP-A701 [#SEC-8K-2026-05-07]. The evidence supports optionality, not validated efficacy or commercialization.
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology